💨 Abstract

Vinay Prasad, the FDA's vaccine chief, is leaving after controversies and criticisms. He joined the FDA in May, bringing his academic critiques of the FDA's drug approval and vaccine policies. He faced backlash from conservative groups, biotech firms, and patient organizations, particularly over his handling of a gene therapy for Duchenne's muscular dystrophy and his rejection of new gene therapy approvals. These actions were seen as opposing the proponents of quicker and wider access to experimental drugs.

Courtesy: WTOP Staff